EVO News and Press, Evotec SE From 09/26/23

LAB eN² WILL INVOLVE INSTITUTIONS INCLUDING HARVARD UNIVERSITY, MASS GENERAL BRIGHAM, AND BETH ISRAEL DEACONESS MEDICAL CENTER FOCUS OF THE COLLABORATION IS TO ACCELERATE THE TRANSLATION OF ACADEMIC IDEAS TO THERAPEUTIC PRODUCT CANDIDATES IN THE CARDIOMETABOLIC SPACE HAMBURG, GERMA...

2023-08-29 15:06:09 ET Evotec SE (EVOTF) Q2 2023 Earnings Conference Call August 29, 2023, 8:00 a.m. ET Company Participants Werner Lanthaler - CEO Laetitia Rouxel - CFO Cord Dohrmann - CSO Matthias Evers - Chief Business Officer Conference Call Partici...

2023-08-29 03:27:45 ET More on Evotec SE: Evotec: R&D, Customer Growth Not Enough To Offset Headwinds Bristol Myers inks licensing pact under Evotec neuroscience deal Evotec unit wins U.S. govt. contract to develop antibody products Seeking Alpha’s...

NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced its financial results and corp...

HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. The Company is going to hold a conference call to discuss...

HAMBURG, GERMANY / ACCESSWIRE / July 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it is adjusting its guidance for the fiscal year 2023. Due to the impact of the cyber-attack, the company now expec...

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN...

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVERY, AND AI-DRIVEN DE NOVO ANTIBODY DESIGN OF THERAPEUTIC CANDIDATES EVOTEC WILL PROVIDE...

2023-06-30 14:38:56 ET Summary Evotec SE caught a 34% bid over the last 6 months. Despite growth in customers and R&D partnerships, further clarifications are needed for the investor to avoid buying on speculation. Whilst emerging trends in the firm's operations are constr...

PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / June 29, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX...